Merck and Moderna maintain a long-standing collaboration on individualized mRNA cancer therapies, most recently highlighted by the August 19, 2026, positive Phase 3 INTerpath-001 readout for intismeran autogene plus Keytruda in resected melanoma, which met recurrence-free and distant metastasis-free survival endpoints. This outcome drove sharp share price gains for both companies and renewed analyst commentary on potential strategic consolidation, including one September 16 assessment suggesting Merck could acquire Moderna near $210–$215 per share to consolidate economics ahead of Keytruda patent pressures. However, no definitive merger or acquisition agreement has been disclosed, and Merck has pursued other deals such as its earlier Terns Pharmaceuticals purchase. With regulatory filings and additional trial expansions now the nearer-term focus, market-implied odds heavily favor no announcement before year-end.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоMerck & Moderna merger/acquisition announced in 2026?
Merck & Moderna merger/acquisition announced in 2026?
24% шанс
НОВЕ
НОВЕ
Dec 31, 2026
24% шанс
НОВЕ
НОВЕ
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration on individualized mRNA cancer therapies, most recently highlighted by the August 19, 2026, positive Phase 3 INTerpath-001 readout for intismeran autogene plus Keytruda in resected melanoma, which met recurrence-free and distant metastasis-free survival endpoints. This outcome drove sharp share price gains for both companies and renewed analyst commentary on potential strategic consolidation, including one September 16 assessment suggesting Merck could acquire Moderna near $210–$215 per share to consolidate economics ahead of Keytruda patent pressures. However, no definitive merger or acquisition agreement has been disclosed, and Merck has pursued other deals such as its earlier Terns Pharmaceuticals purchase. With regulatory filings and additional trial expansions now the nearer-term focus, market-implied odds heavily favor no announcement before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Ринок відкрито: Aug 19, 2026, 3:58 PM ET
Обсяг
$458Дата завершення
Jan 1, 2027Ринок відкрито
Aug 19, 2026, 3:58 PM ETВирішувач
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration on individualized mRNA cancer therapies, most recently highlighted by the August 19, 2026, positive Phase 3 INTerpath-001 readout for intismeran autogene plus Keytruda in resected melanoma, which met recurrence-free and distant metastasis-free survival endpoints. This outcome drove sharp share price gains for both companies and renewed analyst commentary on potential strategic consolidation, including one September 16 assessment suggesting Merck could acquire Moderna near $210–$215 per share to consolidate economics ahead of Keytruda patent pressures. However, no definitive merger or acquisition agreement has been disclosed, and Merck has pursued other deals such as its earlier Terns Pharmaceuticals purchase. With regulatory filings and additional trial expansions now the nearer-term focus, market-implied odds heavily favor no announcement before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Обсяг
$458Дата завершення
Jan 1, 2027Ринок відкрито
Aug 19, 2026, 3:58 PM ETВирішувач
0x65070BE91...Merck and Moderna maintain a long-standing collaboration on individualized mRNA cancer therapies, most recently highlighted by the August 19, 2026, positive Phase 3 INTerpath-001 readout for intismeran autogene plus Keytruda in resected melanoma, which met recurrence-free and distant metastasis-free survival endpoints. This outcome drove sharp share price gains for both companies and renewed analyst commentary on potential strategic consolidation, including one September 16 assessment suggesting Merck could acquire Moderna near $210–$215 per share to consolidate economics ahead of Keytruda patent pressures. However, no definitive merger or acquisition agreement has been disclosed, and Merck has pursued other deals such as its earlier Terns Pharmaceuticals purchase. With regulatory filings and additional trial expansions now the nearer-term focus, market-implied odds heavily favor no announcement before year-end.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання